Use of a non-hepatic cell line highlights limitations associated with cell-based assessment of metabolically induced toxicity

References

• Augustin, E., et al., 2014. CYP3A4-dependent cellular response does not relate to CYP3A4-catalysed metabolites of C-1748 and C-1305 acridine antitumor agents in HepG2 cells. Cell Biology International, 38 (11), 1291–1303.
   PubMed Web of Science ®Google Scholar
• Ayajiki, K., et al., 2003. Mediation of arachidonic acid metabolite(s) produced by endothelial cytochrome P-450 3A4 in monkey arterial relaxation. Hypertension Research, 26 (3), 237–243.
   PubMed Web of Science ®Google Scholar
• Dambach, D.M., Andrews, B.A., and Moulin, F., 2005. New technologies and screening strategies for hepatotoxicity: use of in vitro models. Toxicologic Pathology, 33 (1), 17–26.
   PubMed Web of Science ®Google Scholar
• Donato, M.T., et al., 2004. Fluorescence-based assays for screening nine cytochrome P450 (P450) activities in intact cells expressing individual human P450 enzymes. Drug Metabolism and Disposition, 32 (7), 699–706.
   PubMed Web of Science ®Google Scholar
• Du, Y., et al., 2014. Human hepatocytes with drug metabolic function induced from fibroblasts by lineage reprogramming. Cell Stem Cell, 14 (3), 394–403.
   PubMed Web of Science ®Google Scholar
• Gomez.-Lechon., M.J., Tolosa, L., and Donato.M.T., 2014. Cell-based models to predict human hepatotoxicity of drugs. Revista de Toxicologia, 31, 149–156.
   Google Scholar
• Gómez-Lechón, M.J., Tolosa, L., and Donato, M.T., 2016. Metabolic activation and drug-induced liver injury: In vitro approaches for the safety risk assessment of new drugs. Journal of Applied Toxicology, 36 (6), 752–768.
   PubMed Web of Science ®Google Scholar
• Greer, M.L., et al., 2010. Cell based approaches for evaluation of drug-induced liver injury. Toxicology, 268 (3), 125–131.
   PubMed Web of Science ®Google Scholar
• Grimm, S.W., et al., 1994. Catalytic selectivity and mechanism-based inactivation of stably expressed and hepatic cytochromes P450 2B4 and 2B5: implications of the cytochrome P450 2B5 polymorphism. Molecular Pharmacology, 46, 1090–1099.
   PubMed Web of Science ®Google Scholar
• Guillén, M.I., et al., 1998. Oncostatin M down-regulates basal and induced cytochromes P450 in human hepatocytes. The Journal of Pharmacology and Experimental Therapeutics, 285 (1), 127–134.
   PubMed Web of Science ®Google Scholar
• Gunness, P., et al., 2013. 3D organotypic cultures of human heparg cells: a tool for in vitro toxicity studies. Toxicological Sciences, 133 (1), 67–78.
   PubMed Web of Science ®Google Scholar
• Gupta, R.P., et al., 2004. CYP3A4 is a human microsomal vitamin D 25-hydroxylase. Journal of Bone and Mineral Research, 19 (4), 680–688.
   PubMed Web of Science ®Google Scholar
• Gustafsson, F., et al., 2014. A correlation between the in vitro drug toxicity of drugs to cell lines that express human p450s and their propensity to cause liver injury in humans. Toxicological Sciences, 137 (1), 189–211.
   PubMed Web of Science ®Google Scholar
• Hashizume, T., et al., 2010. Advantages of human hepatocyte-derived transformants expressing a series of human cytochrome P450 isoforms for genotoxicity examination. Toxicological Sciences, 116 (2), 488–497.
   PubMed Web of Science ®Google Scholar
• Hosomi, H., et al., 2011. Development of a highly sensitive cytotoxicity assay system for CYP3A4-mediated metabolic activation. Drug Metabolism and Disposition, 39 (8), 1388–1395.
   PubMed Web of Science ®Google Scholar
• Hughes, J.P., et al., 2011. Principles of early drug discovery. British Journal of Pharmacology, 162 (6), 1239–1249.
   PubMed Web of Science ®Google Scholar
• Laemmli, U.K., 1970. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature, 227 (5259), 680–685.
   PubMed Web of Science ®Google Scholar
• Liebmann, J.E., et al., 1993. Cytotoxic studies of pacfitaxel (Taxol®) in human tumour cell lines. British Journal of Cancer, 68 (6), 1104–1109.
   PubMed Web of Science ®Google Scholar
• Liu, Y., et al., 2015. Evaluation of CYP3A4 inhibition and hepatotoxicity using DMSO-treated human hepatoma HuH-7 cells. Cell Biology and Toxicology, 31 (4–5), 221–230.
   PubMed Web of Science ®Google Scholar
• Mohedas, A.H., et al., 2014. Structure-activity relationship of 3,5-diaryl-2-aminopyridine ALK2 inhibitors reveals unaltered binding affinity for fibrodysplasia ossificans progressiva causing mutants. Journal of Medicinal Chemistry, 57 (19), 7900–7915.
   PubMed Web of Science ®Google Scholar
• Mohedas, A.H., et al., 2013. Development of an ALK2-biased BMP type I receptor kinase inhibitor. ACS Chemical Biology, 8 (6), 1291–1302.
   PubMed Web of Science ®Google Scholar
• Murayama, N., et al., 2001. Expression of CYP2A6 in tumor cells augments cellular sensitivity to Tegafur. Japanese Journal of Cancer Research, 92 (5), 524–528.
   PubMedGoogle Scholar
• O’Brien, P.J., et al., 2006. High concordance of drug-induced human hepatotoxicity with in vitro cytotoxicity measured in a novel cell-based model using high content screening. Archives of Toxicology, 80 (9), 580–604.
   PubMed Web of Science ®Google Scholar
• Oguro, A., et al., 2011. Overexpression of CYP3A4, but not of CYP2D6, promotes hypoxic response and cell growth of Hep3B cells. Drug Metabolism and Pharmacokinetics, 26 (4), 407–415.
   PubMed Web of Science ®Google Scholar
• Oscarson, M., et al., 2002. Characterization of a novelCYP2A7/CYP2A6 hybrid allele (CYP2A6*12) that causes reduced CYP2A6 activity. Human Mutation, 20 (4), 275–283.
   PubMed Web of Science ®Google Scholar
• Ott, L.M., Ramachandran, K., and Stehno-Bittel, L., 2017. An Automated multiplexed hepatotoxicity and CYP induction assay using HepaRG cells in 2D and 3D. SLAS Discovery, 22 (5), 614–625.
   PubMed Web of Science ®Google Scholar
• Park, K., et al., 2005. Investigation of toxic metabolites during drug development. Toxicology and Applied Pharmacology, 207 (2), 425–434.
   PubMedGoogle Scholar
• Potente, M., et al., 2002. Cytochrome P450 2C9-induced endothelial cell proliferation involves induction of mitogen-activated protein (MAP) kinase phosphatase-1, inhibition of the c-Jun N-terminal kinase, and up-regulation of cyclin D1. Journal of Biological Chemistry, 277 (18), 15671–15676.
   PubMed Web of Science ®Google Scholar
• Rana, P., et al., 2016. Development of a cell viability assay to assess drug metabolite structure–toxicity relationships. Bioorganic and Medicinal Chemistry Letters, 26 (16), 4003–4006.
   PubMed Web of Science ®Google Scholar
• Renwick, A.B., et al., 2001. Metabolism of 2,5-bis(trifluoromethyl)-7-benzyloxy-4-trifluoromethylcoumarin by human hepatic CYP isoforms: evidence for selectivity towards CYP3A4. Xenobiotica, 31 (4), 187–204.
   PubMed Web of Science ®Google Scholar
• Scannell, J.W. and Bosley, J., 2016. When quality beats quantity: decision theory, drug discovery, and the reproducibility crisis. PLoS ONE, 11 (2), 1–21.
   Web of Science ®Google Scholar
• Sison-Young, R.L., et al., 2017. A multicenter assessment of single-cell models aligned to standard measures of cell health for prediction of acute hepatotoxicity. Archives of Toxicology, 91 (3), 1385–1400.
   PubMed Web of Science ®Google Scholar
• Sridar, C., et al., 2008. Differential inhibition of cytochromes P450 3A4 and 3A5 by the newly synthesized coumarin derivatives 7-coumarin propargyl ether and 7-(4-trifluoromethyl)coumarin propargyl ether. Drug Metabolism and Disposition, 36 (11), 2234–2243.
   PubMed Web of Science ®Google Scholar
• Thuy Phuong, N.T., et al., 2017. Role of the CYP3A4-mediated 11,12-epoxyeicosatrienoic acid pathway in the development of tamoxifen-resistant breast cancer. Oncotarget, 8 (41), 71054–71069.
   PubMedGoogle Scholar
• Tolosa, L., et al., 2016. Advantageous use of HepaRG cells for the screening and mechanistic study of drug-induced steatosis. Toxicology and Applied Pharmacology, 302, 1–9.
   PubMed Web of Science ®Google Scholar
• Tolosa, L., et al., 2017. Customised in vitro model to detect human metabolism-dependent idiosyncratic drug-induced liver injury. Archives of Toxicology, 92 (1), 383399.
   Web of Science ®Google Scholar
• Tomida, T., et al., 2015. Multiparametric assay using HepaRG cells for predicting drug-induced liver injury. Toxicology Letters, 236 (1), 16–24.
   PubMed Web of Science ®Google Scholar
• Towbin, H., Staehelin, T., and Gordon, J., 1979. Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: procedure and some applications. Proceedings of the National Academy of Sciences of the United States of America, 76 (9), 4350–4354.
   PubMed Web of Science ®Google Scholar
• Trottier, Y., Waithe, W.I., and Anderson, A., 1992. The detection of promutagen activation by extracts of cells expressing cytochrome P450IA2 cDNA: preincubation dramatically increases revertant yield in the Ames test. Mutation Research, 281 (1), 39–45.
   PubMedGoogle Scholar
• Valeriote, F. and Putten, L.V., 1975. Proliferation-dependent cytotoxicity of anticancer agents: a review. Cancer Research, 35 (10), 2619–2630.
   PubMed Web of Science ®Google Scholar
• Wang, J. and Urban, L., 2004. The impact of early ADME profiling on drug discovery and development strategy. Drug Discovery World, 73–86.
   Google Scholar
• Wang, X., et al., 2015. Probing mechanisms of CYP3A time-dependent inhibition using a truncated model system. ACS Medicinal Chemistry Letters, 6 (8), 925–929.
   PubMed Web of Science ®Google Scholar